

## Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

## SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections

Apr 30 2021, 8:00 AM EDT

## SCYNEXIS to Present Two Ibrexafungerp (Brexafemme™) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting

Apr 20 2021, 8:00 AM EDT

## SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Mar 29 2021, 8:20 AM EDT

## Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Market Cap	134.1m
Last Price	\$6.50
52-Week	\$4.21 - \$10.15

05/10/2021 04:00 PM EDT

## Investor Relations

LifeSci Advisors
Irina Koffler
T: 646-970-4681
ikoffler@lifesciadvisors.com

## Leadership

### Marco Taglietti, M.D.

President and Chief Executive Officer

### David Angulo, M.D.

Chief Medical Officer

### Eric Francois

Chief Financial Officer

### Scott Sukenick

General Counsel

### Nkechi Azie, M.D., FIDSA

Vice President, Clinical Development and Medical Affairs

### Jim Maffezzoli

Vice President, Marketing and Sales

### Rajeshwar Motheram, Ph.D.

Senior Vice President, Pharmaceutical Development and Supply Chain

### Glen D. Park, PharmD, MSJ

Vice President, Regulatory Affairs & Quality Assurance

---

## SCYNEXIS, Inc.

1 Evertrust Plaza  
13th Floor  
Jersey City, NJ 07302

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.